Kimball Electronics, Inc. (NASDAQ: KE) – Q3 2026 Earnings
Kimball Electronics, Inc. (NASDAQ: KE) – Q3 2026 Earnings
Press release and earnings call link
Section 1: Short Tear Sheeet
Kimball Electronics is a contract manufacturer that provides Electronics Manufacturing Services (EMS) and Contract Manufacturing Organization (CMO) solutions, mainly for automotive, medical, and industrial customers. The company’s historical base has been automotive-heavy, but management is actively shifting the portfolio toward medical CMO, a higher-strategic-value vertical tied to outsourced manufacturing of medical devices and related products. Q3 FY2026 looked weak on the surface because revenue declined 6% year over year to $352.9 million, but the call reframed the quarter as a medical-led transition story: adjusted for a prior-year one-time medical inventory sale, total company revenue was up nearly 1%, and medical revenue was up 17%. The near-term story is not clean growth yet; it is a mix of medical CMO ramp, margin pressure from facility investment, automotive EV demand uncertainty, and industrial softness. Longer term, management is positioning KE as a more specialized medical manufacturing partner with potential M&A support.
Quarterly Results
Earnings Release Date: May 5, 2026
Stock Price: $26.88
Market Cap: $657.7 million
Q3 2026 sales of $352.9 million vs $374.6 million in the prior year
Q3 2026 Non-GAAP Adjusted EPS of $0.33 vs $0.27 in the prior year
Q3 2026 GAAP Diluted EPS of $0.23 vs $0.15 in the prior year
Quick Takeaway
Kimball Electronics is in a strategic transition phase, shifting from a more cyclical EMS manufacturer toward a medical CMO growth platform. The call’s strongest positive was that normalized medical revenue grew 17%, with medical now representing 30% of total sales and supported by a major Indianapolis facility ramp. However, investors should not ignore the cost of the transition: FY2027 gross margin pressure, 18–36 month program ramp timelines, and macro weakness in automotive and industrial remain real risks. Execution on medical customer wins, facility utilization, and margin recovery will be critical.
Press Release vs Call Transcript Comparison
The quarter is best read as a transition quarter, not a clean growth quarter. The company is still dealing with automotive and industrial softness, but the call makes a stronger case that medical CMO is becoming the dominant strategic story. Medical now represents about 30% of company sales, and management is trying to use facility investment, new customer wins, and potential M&A to make that mix shift more durable.
The press release presents management’s message in a controlled way: sequential growth, positive cash flow, stable adjusted margin, affirmed guidance. The call adds the important nuance: normalized growth is better than reported, but FY2027 margins may be pressured before the facility scales. That makes the investment debate more balanced: investors need to decide whether near-term facility drag is acceptable in exchange for a potentially higher-quality medical manufacturing platform.
The cash flow story is quietly constructive. The release highlights the ninth consecutive quarter of positive operating cash generation, while the call adds that inventory was down $23.3 million, or 8%, year over year, and that working capital management is improving. For a contract manufacturer, cash conversion days (CCD, a working capital efficiency metric) matter because the business can consume cash when inventory and receivables rise. KE’s 90 CCD level is still a meaningful working capital burden, but the improvement is directionally positive.
Investor Underappreciation Signals
✅Normalized medical growth — Medical looked down 8% in the press release, but the call clarified it was up 17% after adjusting for last year’s non-recurring inventory sale, which could shift perception if investors begin valuing KE as a medical CMO growth story rather than a declining EMS manufacturer.
✅Indianapolis capacity optionality — The call revealed customer tours, clean room installation, lift-and-shift discussions, and expected production by year-end, which may be overlooked because the press release only referred broadly to medical CMO investment.
✅FY2027 margin dip may be investment-driven, not deterioration — Management warned of 40–50 basis points of gross margin pressure from duplicative facility costs, but this could be misread as operational weakness unless investors understand it is tied to ramping a larger medical platform.
✅M&A is more actionable than the release suggests — The press release lightly mentions inorganic growth, while the call describes target capabilities, geographies, customers, and liquidity, suggesting a deal could become a real catalyst.
✅New medical customer goal is on track — The call disclosed that KE is targeting five new medical customers annually and is on target, which is easy to miss but important because new logos are central to filling the Indianapolis facility.
✅Asia medical strength — The call disclosed that Q3 medical growth in Asia was over 20%, suggesting that medical momentum is not just a North American facility story but also supported by global demand through Thailand and other export-oriented capacity.
Section 2: Supplementary Information
Positive Insights
Negative Insights
Tariff Risk
The transcript did not include a direct discussion of U.S. tariffs or trade policy using the word “tariff.” However, management did discuss related trade and supply-chain risks indirectly. The company is monitoring the impact of war involving Iran, including higher freight costs, raw material costs, gas prices, and consumer sentiment. These factors could pressure profitability if they increase input or logistics costs faster than KE can offset them.
The transcript also implies some supply-chain positioning benefits. Management said established medical manufacturers outside the U.S. may seek domestic market entry and scaled U.S. production, and that customers are looking for U.S. footprint. The Indianapolis facility could therefore become more strategically valuable if customers want domestic production to reduce geopolitical, logistics, or trade-policy exposure.
No specific tariff mitigation actions were described, such as pricing changes, contract renegotiations, supplier shifts, or production relocation specifically tied to tariffs. Investors should monitor whether future calls discuss pass-through pricing, customer cost sharing, or geographic production shifts if trade policy becomes a larger issue.
Hot Stock Trends Analysis
Previous Earnings Call
Quarter-over-quarter comparison (Previous Analysis)
In Q2, Kimball’s narrative was about strategic transformation: management raised guidance, celebrated the Indianapolis medical facility, highlighted the coming Kimball Solutions rebrand, and framed medical CMO as the company’s future growth engine. The message was that KE was evolving beyond traditional EMS and using medical, European automotive ramps, and restructuring benefits to return toward profitable growth.By Q3, the story evolved into execution and proof points. Management still emphasized medical CMO, but now the focus was on normalized medical growth, customer tours, new logo targets, facility production timing, M&A readiness, and working capital discipline. At the same time, the call introduced more sober realities: FY2027 margin drag from the facility ramp, automotive EV demand uncertainty, industrial softness, and geopolitical cost risks. The narrative is still constructive, but it has shifted from “the strategy is launching” to “the strategy is working, but the next phase requires execution through cost and demand volatility.”
Year-over-year comparison (Previous Analysis)
In Q3 FY2025, Kimball’s story was about stabilizing a weakened business and repositioning for future growth. Management was still dealing with revenue declines, lower absorption, tariff uncertainty, Tampa closure, AT&M divestiture, and inventory reduction, while introducing the Indianapolis medical CMO facility as a long-term strategic bet. The medical story was promising, but the quarter’s reported medical growth was clouded by a one-time consigned inventory sale.
By Q3 FY2026, the narrative had evolved into early evidence that the repositioning is working, but with execution risk still ahead. Medical growth was no longer just a strategic aspiration; management cited 17% normalized medical growth, 30% revenue mix, new customer targets, customer tours, lift-and-shift discussions, and M&A readiness. However, the company also made clear that FY2027 will carry facility-related margin pressure, while automotive and industrial remain exposed to macro and demand volatility. In short, KE moved from “repair and reposition” to “medical-led execution phase,” with the next test being whether Indianapolis can scale fast enough to offset the cost drag.